Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

REGN Regeneron Pharmaceuticals

Trading 11-22 10:17:01 EST

747.99

+3.49

+0.47%

High749.78	Low742.00	Vol186.81K
Open744.70	D1 Closing744.50	Amplitude1.05%
Mkt Cap82.20B	Tradable Cap79.29B	Total Shares109.89M
T/O139.35M	T/O Rate0.18%	Tradable Shares106.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"Regeneron Pharmaceuticals","latestPrice":747.99,"timestamp":1732288621429,"preClose":744.5,"halted":0,"volume":186813,"delay":0,"floatShares":106000000,"shares":109889531,"eps":40.428474,"marketStatus":"Trading","change":3.49,"latestTime":"11-22 10:17:01 EST","open":744.7,"high":749.7831,"low":742,"amount":139349776.0347,"amplitude":0.010454,"askPrice":748.84,"askSize":100,"bidPrice":747.34,"bidSize":206,"shortable":3,"etf":0,"ttmEps":40.428474,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1732309200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":744.5,"preHourTrading":{"tag":"盘前","latestPrice":749.69,"preClose":744.5,"latestTime":"09:26 EST","volume":308,"amount":230175.5456,"timestamp":1732285561547},"postHourTrading":{"tag":"盘后","latestPrice":744.5,"preClose":744.5,"latestTime":"19:57 EST","volume":145613,"amount":108409196.51,"timestamp":1732237070902},"volumeRatio":1.514862,"impliedVol":0.3242,"impliedVolPercentile":0.8452},"requestUrl":"/m/hq/s/REGN","defaultTab":"news","newsList":[{"id":"2485426607","title":"Regeneron Pharmaceuticals Inc. Stock Rises Thursday, Still Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2485426607","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485426607?lang=en_us&edition=fundamental","pubTime":"2024-11-22 05:46","pubTimestamp":1732225560,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Regeneron Pharmaceuticals Inc.  inched 0.15% higher to $744.50 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index  rising 0.53% to 5,948.71 and the Dow Jones Industrial Average  rising 1.06% to 43,870.35.The stock's rise snapped a two-day losing streak.Regeneron Pharmaceuticals Inc. closed $466.70 below its 52-week high , which the company achieved on August 27th.The stock underperformed when compared to some of its competitors Thursday, as Amgen Inc.  rose 0.71% to $289.90, Moderna Inc.  rose 3.55% to $38.25, and Gilead Sciences Inc.  rose 1.27% to $89.76.Trading volume  eclipsed its 50-day average volume of 769,998.Data source: Dow Jones Market Data, FactSet. Data compiled November 21, 2024.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow J","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"gpt_icon":0},{"id":"2485417620","title":"Regeneron Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2485417620","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485417620?lang=en_us&edition=fundamental","pubTime":"2024-11-21 05:45","pubTimestamp":1732139100,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Regeneron Pharmaceuticals Inc.  slipped 0.17% to $743.35 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index  remaining mostly unchanged at 5,917.11 and the Dow Jones Industrial Average  rising 0.32% to 43,408.47.This was the stock's second consecutive day of losses.Regeneron Pharmaceuticals Inc. closed $467.85 below its 52-week high , which the company reached on August 27th.The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Amgen Inc.  rose 2.83% to $287.87, Moderna Inc.  fell 0.94% to $36.94, and Gilead Sciences Inc.  rose 1.00% to $88.63.Trading volume  remained 112,151 below its 50-day average volume of 766,545.Data source: Dow Jones Market Data, FactSet. Data compiled November 20, 2024.This content was created by MarketWatch, which is operated by Dow Jones & Co. Market","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"gpt_icon":0},{"id":"2484148710","title":"China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2484148710","media":"Reuters","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484148710?lang=en_us&edition=fundamental","pubTime":"2024-11-20 23:07","pubTimestamp":1732115266,"startTime":"0","endTime":"0","summary":"China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug Nov 20 (Reuters) - Eli Lilly LLY.N and Hong Kong-listed Laekna 2105.HK will collaborate to develop an experimen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nL4N3MR128:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868836914.USD","LU0106261372.USD","LU0640476718.USD","LU2491050154.USD","SG9999001176.SGD","LU0061475181.USD","LU1023059063.AUD","LU1712237335.SGD","LU2362541513.USD","SGXZ99366536.SGD","LU0097036916.USD","LU0109394709.USD","LU0238689110.USD","LU1366192091.USD","LU0417517546.SGD","SG9999015986.USD","REGN","LU0079474960.USD","SGXZ81514606.USD","BK4007","LU1814569148.SGD","SG9999001176.USD","LU1868837136.USD","LU2237443895.HKD","LU1064131342.USD","LU2360106947.USD","LU2265009873.SGD","LU1917777945.USD","IE00BK4W5M84.HKD","LU0466842654.USD","SGXZ31699556.SGD","IE0004445239.USD","LU2361044865.SGD","LU1061106388.HKD","LU2237443382.USD","LU0882574055.USD","LU0256863811.USD","IE00B2B36J28.USD","LLY","02105","LU1035775433.USD","LU1267930730.SGD","LU2063271972.USD","SG9999014898.SGD","BK4588","LU0198837287.USD","LU0385154629.USD","SRRK","LU2112291526.USD","LU1551013425.SGD"],"gpt_icon":1},{"id":"2484750183","title":"Regeneron Pharmaceuticals, Inc. (REGN): Among the Best Genomics Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2484750183","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484750183?lang=en_us&edition=fundamental","pubTime":"2024-11-20 07:51","pubTimestamp":1732060310,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now.In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc.  stands against the other genomics stocks.Genomics is the study of genes and how they function. Many rapidly growing companies are emerging in the genomics field as technological advances substantially reduce the cost, accuracy, and time required to map a human being's genome.The fields of gene editing and cell and gene therapies  are also developing quickly. The UK approved Casgevy for sickle cell disease and β-thalassemia, pointing out the potential of CRISPR gene editing. According to Deloitte’s research report, the growing market for CGTs, from US$5.3 billion in 2022 to $19.9 billion in 2027, signals a shift towards customized advanced medicine despite high costs leading innovative business models. Furthermore,","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/jCXZp.ZhWMqygm6VLIkk4w--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/9b67531d4ce9e2fbb21fef60675f48d3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/jCXZp.ZhWMqygm6VLIkk4w--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/9b67531d4ce9e2fbb21fef60675f48d3"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/regeneron-pharmaceuticals-inc-regn-among-235150907.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","LU2362541273.HKD","LU2362541513.USD","LU0053666078.USD","LU1917777945.USD","BK4139","LU2023250504.SGD","LU0114720955.EUR","LU2106854487.HKD","SQQQ","PSQ","QID","REGN","LU0109394709.USD","NQmain","BK4585","LU2468319806.SGD","LU2362540622.SGD","LU0889565916.HKD","LU0320765992.SGD",".IXIC","MNQmain","TQQQ","LU0289739699.SGD","LU1974910355.USD","LU2089984988.USD","QLD","LU0823416689.USD","LU0882574055.USD","LU0058720904.USD"],"gpt_icon":1},{"id":"2484035699","title":"Regeneron: The Biotech Stock To Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2484035699","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484035699?lang=en_us&edition=fundamental","pubTime":"2024-11-20 04:52","pubTimestamp":1732049575,"startTime":"0","endTime":"0","summary":"Biotech stocks, including Regeneron, have seen significant declines due to regulatory and political uncertainty, presenting a potential buying opportunity as seller exhaustion nears.Regeneron's 40% drop is driven by multiple factors, including Eylea's market share concerns, DOJ lawsuits, and general sector uneasiness.Despite the drop, Regeneron remains a highly profitable company with a robust pipeline, trading at a dirt-cheap valuation and offering long-term growth potential.   Solskin Have you looked at biotech stocks lately?Wall Street darlings like Regeneron Pharmaceuticals, Inc. , Amgen Inc. , and many other healthcare and biotech stocks have been demolished in recent trading sessions. Even the well-diversified iShares Biotechnology ETF (","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/168166178/image_168166178.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/168166178/image_168166178.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4738788-regeneron-the-biotech-stock-to-buy-now","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["LU0114720955.EUR","LU0109394709.USD","LU1974910355.USD","LU1917777945.USD","LU2089984988.USD","LU2106854487.HKD","LU2362540622.SGD","LU2362541513.USD","LU0882574055.USD","LU0053666078.USD","LU0058720904.USD","BK4588","LU2023250504.SGD","BK4585","LU0823416689.USD","LU0889565916.HKD","LU0289739699.SGD","REGN","LU2468319806.SGD","BK4139","LU2362541273.HKD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2484924348","title":"Here’s Why Regeneron Pharmaceuticals (REGN) Declined in Q3","url":"https://stock-news.laohu8.com/highlight/detail?id=2484924348","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484924348?lang=en_us&edition=fundamental","pubTime":"2024-11-19 23:16","pubTimestamp":1732029400,"startTime":"0","endTime":"0","summary":"Bronte Capital, an investment management company, released its “Amalthea Fund” third-quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund was down 3.72% for the quarter vs. +2.54% for the MSCI ACWI . It was down 5.59% in September vs. -0.35% for the index. The market rose in the third quarter, reaching new peaks, with a minor dip in late August and early September. In addition, you can check the top 5 holdings of the fund to know its best picks in 2024.Amalthea Fund stated the following regarding Regeneron Pharmaceuticals, Inc.  in its Q3 2024 investor letter:. Inanother article, we discussed Regeneron Pharmaceuticals, Inc.  and shared Baron Health Care Fund's views on the company. In addition, please check out ou","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/4QP5B8ZNYo7hDgTmnS7DbQ--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/bae404889492a528436e130b89e988f3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/4QP5B8ZNYo7hDgTmnS7DbQ--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/bae404889492a528436e130b89e988f3"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-regeneron-pharmaceuticals-regn-declined-151640049.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2023250504.SGD","LU2468319806.SGD","QLD","BK4588","LU2362541513.USD","QID","LU0114720955.EUR","PSQ","SQQQ","LU0053666078.USD","LU0058720904.USD","LU0289739699.SGD","LU2362541273.HKD","LU0882574055.USD","REGN","BK4585","LU2362540622.SGD",".IXIC","LU0320765992.SGD","LU0823416689.USD","LU2106854487.HKD","LU1917777945.USD","BK4139","MNQmain","LU0889565916.HKD","TQQQ","LU2089984988.USD","NQmain","LU1974910355.USD","LU0109394709.USD"],"gpt_icon":1},{"id":"2484847929","title":"Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2484847929","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484847929?lang=en_us&edition=fundamental","pubTime":"2024-11-19 05:45","pubTimestamp":1731966300,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Regeneron Pharmaceuticals Inc.  inched 0.69% higher to $762.00 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index  rising 0.39% to 5,893.62 and the Dow Jones Industrial Average  falling 0.13% to 43,389.60.The stock's rise snapped a five-day losing streak.Regeneron Pharmaceuticals Inc. closed $449.20 below its 52-week high , which the company reached on August 27th.The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Amgen Inc.  fell 0.92% to $278.76, Moderna Inc.  rose 7.22% to $39.51, and Gilead Sciences Inc.  rose 0.07% to $88.46.Trading volume  eclipsed its 50-day average volume of 743,786.Data source: Dow Jones Market Data, FactSet. Data compiled November 18, 2024.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independentl","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"gpt_icon":0},{"id":"2484984151","title":"FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria","url":"https://stock-news.laohu8.com/highlight/detail?id=2484984151","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484984151?lang=en_us&edition=fundamental","pubTime":"2024-11-19 04:00","pubTimestamp":1731960000,"startTime":"0","endTime":"0","summary":"Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their resubmitted supplemental biologics license application  seeking approval of Dupixent for the treatment of chronic spontaneous urticaria .The sBLA seeks approval for CSU in people aged 12 years and older whose disease is not adequately controlled with existing therapies like H1 antihistamines. The FDA’s decision on the sBLA is expected on April 18, 2025.The FDA had issued a complete response letter  for the first sBLA seeking approval of Dupixent for CSU in October last year for want of more data.Sanofi’s stock has declined 3.5% so far this year against an increase of 3.4% for the industry.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/HNGK8KXbnuM7D3xIxBkleg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/00ec4a55c0f0d99f7e816f5da7894e0c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/HNGK8KXbnuM7D3xIxBkleg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/00ec4a55c0f0d99f7e816f5da7894e0c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-accepts-sny-regns-dupixent-200000522.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4533","GILD","LU2362540622.SGD","LU0109394709.USD","LU0868494617.USD","LU0306807586.USD","SG9999002224.SGD","SG9999003800.SGD","REGN","LU0823416689.USD","BK4583","LU0321505439.SGD","LU2468319806.SGD","LU0234570918.USD","BK4592","BK4534","LU0114720955.EUR","LU1430594728.SGD","LU1057294990.SGD","LU2106854487.HKD","CRL","BK4585","LU1066051498.USD","LU2023250504.SGD","IE0002270589.USD","PFE","BK4566","IE00B19Z3B42.SGD","BK4578","BK4121","BK4532","BK4530","LU1894683348.USD","LU0320765992.SGD","LU0889565916.HKD","LU1974910355.USD","BK4007","IE00BFXG1179.USD","LU2362541273.HKD","SGXZ57979304.SGD","IE00BSNM7G36.USD","LU1023059063.AUD","LU0170899867.USD","SNY","BK4139","LU1839511570.USD","LU0306806265.USD","IE00BKVL7J92.USD","LU0289739699.SGD","IE00BLSP4452.SGD"],"gpt_icon":1},{"id":"2484862900","title":"Deutsche Bank Cuts Regeneron Pharmaceuticals Price Target to $805 From $900, Maintains Hold Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2484862900","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484862900?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:28","pubTimestamp":1731932931,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) has an average rating of outperform and price targets ranging from $800 to $1,230, according to analysts polled by Capital IQ.(MT Newswires covers equity, commodity an","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["REGN","DB"],"gpt_icon":0},{"id":"2483535284","title":"Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses On The Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2483535284","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483535284?lang=en_us&edition=fundamental","pubTime":"2024-11-16 05:45","pubTimestamp":1731707100,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Regeneron Pharmaceuticals Inc.  slid 3.28% to $756.81 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index  falling 1.32% to 5,870.62 and Dow Jones Industrial Average  falling 0.70% to 43,444.99.This was the stock's fifth consecutive day of losses.Regeneron Pharmaceuticals Inc. closed $454.39 below its 52-week high , which the company achieved on August 27th.Despite its losses, the stock outperformed some of its competitors Friday, as Amgen Inc.  fell 4.16% to $283.61, Moderna Inc.  fell 7.34% to $36.85, and Gilead Sciences Inc.  fell 4.03% to $88.40.Trading volume  eclipsed its 50-day average volume of 728,628.Data source: Dow Jones Market Data, FactSet. Data compiled November 15, 2024.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"gpt_icon":0},{"id":"1126233837","title":"Top Calls on Wall Street: Starbucks, United Airlines, Delta Air Lines, Twilio, Morgan Stanley and More","url":"https://stock-news.laohu8.com/highlight/detail?id=1126233837","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126233837?lang=en_us&edition=fundamental","pubTime":"2024-11-15 23:51","pubTimestamp":1731685878,"startTime":"0","endTime":"0","summary":"Here are Friday’s biggest calls on Wall Street:Top 5 Upgrades:Wells Fargo upgraded Morgan Stanley (MS) to Equal Weight from Underweight with a price target of $142, up from $107, as part of a broader ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VCYT","MS","SEDG","BLUE","CMA","DAL","SBUX","UAL","TWLO","REGN","RKT","DRH"],"gpt_icon":1},{"id":"2483432691","title":"Regeneron, Sanofi Get New FDA Review of Dupixent for CSU","url":"https://stock-news.laohu8.com/highlight/detail?id=2483432691","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483432691?lang=en_us&edition=fundamental","pubTime":"2024-11-15 19:12","pubTimestamp":1731669120,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals and Sanofi said the U.S. Food and Drug Administration has accepted their resubmitted application seeking expanded approval of the blockbuster anti-inflammatory drug Dupixent for the inflammatory skin condition chronic spontaneous urticaria, or CSU.Regeneron and Sanofi, which are seeking approval of the drug in patients 12 and older whose disease isn't adequately controlled with H1 antihistamine treatment, on Friday said the FDA set a target action date of April 18, 2025, for a decision.The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in CSU, which causes sudden and debilitating hives and recurring itch.The companies said an FDA green light would make Dupixent the first targeted therapy for CSU in a decade, adding that more than 300,000 people in the U.S. suffer from the condition, which isn't adequately controlled","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362540622.SGD","LU0109394709.USD","LU1917777945.USD","REGN","LU0823416689.USD","LU2468319806.SGD","LU0114720955.EUR","LU2106854487.HKD","LU0053666078.USD","SNYNF","BK4585","LU2023250504.SGD","LU0058720904.USD","LU2362541513.USD","LU1974910355.USD","LU2362541273.HKD","LU0320765992.SGD","BK4588","LU0889565916.HKD","BK4007","IE00BFXG1179.USD","LU0882574055.USD","LU2089984988.USD","SNY","BK4139","LU0289739699.SGD"],"gpt_icon":0},{"id":"2483325791","title":"Wolfe Initiates Regeneron Pharmaceuticals at Outperform With $1,150 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2483325791","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483325791?lang=en_us&edition=fundamental","pubTime":"2024-11-15 19:03","pubTimestamp":1731668632,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) has an average outperform rating and a price target range of $800 to $1,230, according to analysts polled by Capital IQ.(MT Newswires covers equity, commodity and econ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["REGN"],"gpt_icon":0},{"id":"2483341344","title":"Regeneron Pharmaceuticals, Sanofi Say FDA Accepts Application for Skin Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2483341344","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483341344?lang=en_us&edition=fundamental","pubTime":"2024-11-15 17:25","pubTimestamp":1731662708,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals  and Sanofi  said Friday the US Food and Drug Administration has accepted for review a resubmission of the supplemental biologics license application for Dupixent as a potential treatment for patients aged 12 years and older with chronic spontaneous urticaria.Chronic spontaneous urticaria is an inflammatory skin disease that causes debilitating hives and recurring itch.The FDA target action date for a decision on the drug, also known as dupilumab, is April 18.The resubmitted application is supported by newly added results from a phase 3 clinical trial of Dupixent which showed the drug \"significantly reduced\" itch and hives generated by the illness, the companies said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","LU2106854487.HKD","LU2362541273.HKD","BK4007","SNY","LU0289739699.SGD","LU0053666078.USD","LU0889565916.HKD","LU1917777945.USD","LU2362540622.SGD","LU1974910355.USD","LU0109394709.USD","LU2089984988.USD","LU0823416689.USD","LU0320765992.SGD","LU2362541513.USD","LU0114720955.EUR","BK4588","LU2468319806.SGD","IE00BFXG1179.USD","SNYNF","REGN","LU0058720904.USD","LU0882574055.USD","LU2023250504.SGD","BK4139"],"gpt_icon":0},{"id":"2483313845","title":"BRIEF-Dupixent SBLA Accepted For FDA Review For Treatment Of Chronic Spontaneous Urticaria","url":"https://stock-news.laohu8.com/highlight/detail?id=2483313845","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483313845?lang=en_us&edition=fundamental","pubTime":"2024-11-15 14:03","pubTimestamp":1731650580,"startTime":"0","endTime":"0","summary":"BRIEF-Dupixent SBLA Accepted For FDA Review For Treatment Of Chronic Spontaneous UrticariaNov 15 (Reuters) - Sanofi SA SASY.PA:PRESS RELEASE: DUPIXENT SBLA ACCEPTED FOR FDA REVIEW FOR THE TREATMENT OF","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nTUA7F4ZKC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1917777945.USD","LU0289739699.SGD","LU0114720955.EUR","LU1974910355.USD","LU0882574055.USD","LU2362541273.HKD","REGN","LU0320765992.SGD","LU2468319806.SGD","LU0053666078.USD","LU2362541513.USD","BK4585","LU0889565916.HKD","LU2106854487.HKD","LU0058720904.USD","LU0109394709.USD","LU2089984988.USD","BK4139","LU2023250504.SGD","LU0823416689.USD","LU2362540622.SGD","BK4588"],"gpt_icon":0},{"id":"2483331809","title":"Sanofi - Resubmission Includes New Pivotal Data Which Confirm Dupixent Significantly Reduced Itch and Hive Activity","url":"https://stock-news.laohu8.com/highlight/detail?id=2483331809","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483331809?lang=en_us&edition=fundamental","pubTime":"2024-11-15 14:00","pubTimestamp":1731650400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nTUA7F4ZKC:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0109394709.USD","LU0114720955.EUR","LU2468319806.SGD","BK4139","LU0889565916.HKD","LU1917777945.USD","LU2362540622.SGD","LU0058720904.USD","LU2023250504.SGD","LU2106854487.HKD","BK4585","LU0320765992.SGD","LU2362541513.USD","LU0823416689.USD","LU2089984988.USD","LU2362541273.HKD","LU1974910355.USD","LU0882574055.USD","BK4588","REGN","LU0053666078.USD","LU0289739699.SGD"],"gpt_icon":0},{"id":"2483901313","title":"Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria","url":"https://stock-news.laohu8.com/highlight/detail?id=2483901313","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483901313?lang=en_us&edition=fundamental","pubTime":"2024-11-15 14:00","pubTimestamp":1731650400,"startTime":"0","endTime":"0","summary":"Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity. More than 300,000 people in the US suffer from chronic spontaneous urticaria  that is inadequately controlled by antihistamines. FDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decade. Paris and Tarrytown, NY, November 15, 2024. The US Food and Drug Administration  has accepted for review the resubmission of the supplemental biologics license application  for Dupixent  to treat adults and pediatric patients aged 12 years and older with chronic spontaneous urticaria  whose disease is not adequately controlled with H1 antihistamine treatment. The target action date for the FDA decision is April 18, 2025.Dupixent has been approved for CSU in Japan and the United Arab Emirates  and is also under regulatory review in the EU based on earlier study readouts. Outside of Japan and the UAE, the safety and efficacy of","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OPTreMFV4QxkZ_hb1FVJzw--~B/aD0xNjc7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/9e521264632e7a9a44e3450108999128","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OPTreMFV4QxkZ_hb1FVJzw--~B/aD0xNjc7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/9e521264632e7a9a44e3450108999128"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/press-release-dupixent-sbla-accepted-060000634.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2468319806.SGD","LU0053666078.USD","REGN","BK4588","LU2106854487.HKD","LU0823416689.USD","LU0058720904.USD","LU0289739699.SGD","BK4139","UAE","LU0889565916.HKD","LU2362540622.SGD","LU2362541513.USD","BK4007","LU1917777945.USD","LU0882574055.USD","LU1974910355.USD","SNY","LU2023250504.SGD","LU2089984988.USD","IE00BFXG1179.USD","LU0114720955.EUR","BK4585","LU2362541273.HKD","LU0320765992.SGD","LU0109394709.USD"],"gpt_icon":1},{"id":"2483562313","title":"Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483562313","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483562313?lang=en_us&edition=fundamental","pubTime":"2024-11-15 13:59","pubTimestamp":1731650340,"startTime":"0","endTime":"0","summary":"Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antih","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/15/2981762/0/en/Dupixent-dupilumab-sBLA-Accepted-for-FDA-Review-for-the-Treatment-of-Chronic-Spontaneous-Urticaria-CSU.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","SNY","IE00BFXG1179.USD","BK4585","UAE","BK4007","REGN","LU2362540622.SGD","LU2023250504.SGD","LU0882574055.USD","LU0109394709.USD","LU0889565916.HKD","LU2468319806.SGD","LU0053666078.USD","LU0114720955.EUR","LU1974910355.USD","BK4588","BK4139","LU2362541273.HKD","LU2089984988.USD","LU0823416689.USD","LU1917777945.USD","LU2106854487.HKD","LU0320765992.SGD","LU0289739699.SGD","LU2362541513.USD"],"gpt_icon":1},{"id":"2483330705","title":"Vaccine Stocks Slide After Trump Nominates Robert F. Kennedy Jr. to Be Top Health Official","url":"https://stock-news.laohu8.com/highlight/detail?id=2483330705","media":"Yahoo Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483330705?lang=en_us&edition=fundamental","pubTime":"2024-11-15 13:40","pubTimestamp":1731649200,"startTime":"0","endTime":"0","summary":"Vaccine stocks slipped on Thursday after multiple reports indicated President-elect Donald Trump would name anti-vaccine activist Robert F. Kennedy Jr. to lead the Department of Health and Human Servi","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_sg","url":"https://finance.yahoo.com/news/moderna-novovax-stocks-slide-after-trump-nominates-robert-f-kennedy-jr-to-be-top-health-official-212802309.html","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":"8b50228a679c44f870e44bbf889089f6","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/moderna-novovax-stocks-slide-after-trump-nominates-robert-f-kennedy-jr-to-be-top-health-official-212802309.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_sg","symbols":["IE00BBT3K403.USD","SG9999003800.SGD","IE00B19Z3581.USD","LU0456855351.SGD","LU1023059063.AUD","IE00BLSP4452.SGD","LU1066051498.USD","MRNA","LU0306806265.USD","BK4532","GSK","BK4551","LU0225771236.USD","SG9999001176.USD","BK4550","LU0306807586.USD","BK4501","LU0234572021.USD","SGXZ57979304.SGD","NVAX","AMGN","LU1883839398.USD","NVO","PFE","LU0058720904.USD","BK4534","LU0122379950.USD","BK4547","LU1894683264.USD","BK4007","BK4548","BK4533","LU1057294990.SGD","LU0289739699.SGD","REGN","LLY","BK4585","SG9999002224.SGD","BNTX","SG9999002232.USD","LU0321505439.SGD","BK4588","IE0002270589.USD","IE00B19Z3B42.SGD","SG9999011175.SGD","LU0170899867.USD","SNY","BK4592","IE000M9KFDE8.USD","LU0985481810.HKD","LU1066053197.SGD","BK4581","LU0321505868.SGD","LU0225284248.USD","BK4568","SG9999001176.SGD","IE00BLSP4239.USD"],"gpt_icon":1},{"id":"2483357507","title":"Wolfe Research starts Regeneron at Outperform, sees ‘attractive entry point’","url":"https://stock-news.laohu8.com/highlight/detail?id=2483357507","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483357507?lang=en_us&edition=fundamental","pubTime":"2024-11-15 07:40","pubTimestamp":1731627612,"startTime":"0","endTime":"0","summary":"Wolfe Research initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Eylea patent litigation concerns had pressu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/wolfe-research-starts-regeneron-at-outperform-sees-attractive-entry-point?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/wolfe-research-starts-regeneron-at-outperform-sees-attractive-entry-point?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","LU0289739699.SGD","LU0823416689.USD","LU2089984988.USD","LU0882574055.USD","LU2106854487.HKD","LU0320765992.SGD","LU2023250504.SGD","LU2362541513.USD","LU0109394709.USD","BK4139","LU0114720955.EUR","REGN","LU2362541273.HKD","LU1974910355.USD","BK4585","LU1917777945.USD","LU0058720904.USD","LU0053666078.USD","BK4588","LU2468319806.SGD","LU2362540622.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":-0.0486},{"period":"1month","weight":-0.2264},{"period":"3month","weight":-0.3791},{"period":"6month","weight":-0.2442},{"period":"1year","weight":-0.0691},{"period":"ytd","weight":-0.1523}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.041845},{"month":2,"riseRate":0.393939,"avgChangeRate":0.089316},{"month":3,"riseRate":0.484848,"avgChangeRate":-0.042863},{"month":4,"riseRate":0.484848,"avgChangeRate":0.019407},{"month":5,"riseRate":0.647059,"avgChangeRate":0.064499},{"month":6,"riseRate":0.411765,"avgChangeRate":0.00486},{"month":7,"riseRate":0.647059,"avgChangeRate":0.053048},{"month":8,"riseRate":0.529412,"avgChangeRate":0.02165},{"month":9,"riseRate":0.470588,"avgChangeRate":0.0249},{"month":10,"riseRate":0.382353,"avgChangeRate":-0.006135},{"month":11,"riseRate":0.529412,"avgChangeRate":0.041377},{"month":12,"riseRate":0.515152,"avgChangeRate":0.048311}],"exchange":"NASDAQ","name":"Regeneron Pharmaceuticals","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Regeneron Pharmaceuticals(REGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Regeneron Pharmaceuticals,REGN,Regeneron Pharmaceuticals股票,Regeneron Pharmaceuticals股票老虎,Regeneron Pharmaceuticals股票老虎国际,Regeneron Pharmaceuticals行情,Regeneron Pharmaceuticals股票行情,Regeneron Pharmaceuticals股价,Regeneron Pharmaceuticals股市,Regeneron Pharmaceuticals股票价格,Regeneron Pharmaceuticals股票交易,Regeneron Pharmaceuticals股票购买,Regeneron Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Regeneron Pharmaceuticals(REGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction